PT Kalbe Farma Tbk. (FRA:LCLA)

Market Cap	1.62B -41.6%
Revenue (ttm)	1.85B +13.0%
Net Income	176.61M +5.8%
EPS	0.00 +6.8%
Shares Out	n/a
PE Ratio	7.03
Forward PE	8.53
Dividend	0.00 (3.49%)
Ex-Dividend Date	Jun 4, 2026

Volume	41,319
Open	0.0270
Previous Close	0.0270
Day's Range	0.0270 - 0.0275
52-Week Range	0.0235 - 0.0695
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Oct 29, 2026

About PT Kalbe Farma Tbk.

PT Kalbe Farma Tbk., together with its subsidiaries, engages in the development, manufacture, and trading of pharmaceutical products in Indonesia. It operates through Prescription Pharmaceuticals; Consumer Health; Nutritionals; and Distribution and Logistic segments. The company provides prescription/ethical; consumer health; nutritionals; distribution and logistics; health services; medical devices; biopharma; animal health; international business, and E-health products. In addition, the company provides health screening services; operates as ...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1966
• Employees: 12,806
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: LCLA

Financial Performance

In 2025, PT Kalbe Farma Tbk.'s revenue was 35.32 trillion, an increase of 8.27% compared to the previous year's 32.63 trillion. Earnings were 3.66 trillion, an increase of 13.09%.

Financial numbers in IDR

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error